Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 2/3 × Carcinoma in Situ × valrubicin × Clear all

Phase

Phase 2/3 2 Phase 3 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2 Carcinoma in Situ 2 Virus Diseases 1 Neoplasms 1 Carcinoma, Transitional Cell 1 Adenoviridae Infections 1

Interventions

valrubicin 2 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Gemcitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

NCT01316874 2015-06-12

Bladder Cancer

Endo Pharmaceuticals

Phase 2/3 Completed

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡